PT  - JOURNAL ARTICLE
AU  - Toledo, Angie K.
AU  - León-Jimenez, Franco
AU  - Cavalcanti, Sofia
AU  - Vilchez-Barreto, Percy
AU  - Reto, Narcisa
AU  - Vega, Jessica
AU  - Bolivar, Lucia M
AU  - Rhor, Matilde
AU  - Ypanaque, Jhon
AU  - Silva, Henry
AU  - Moyano, Luz M.
AU - Group of Neuroepidemiology and Science of Life of Peru
TI  - High seroprevalence after the second wave of SARS-COV2 respiratory infection in a small settlement on the northern coastal of Peru
AID  - 10.1101/2023.07.19.23292491
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.19.23292491
4099  - http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292491.short
4100  - http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292491.full
AB  - Background Due to more infections from variations that could escape vaccination and immunity by asymptomatic to uninfected transmission, COVID-19’s second wave had higher seroprevalence globally. Public health constraints and herd immunity may not work against these novel variations’ infectivity. This population-based study in Peru’s Tumbes Region during the second wave of COVID-19 seeks to determine seroprevalence and demographic changes from the first wave.Methodology/Principal findings In Dec 2021-Jan 2022, a study in Tumbes’ informal settlement sampled individuals over 2 years old from one in every four households. Finger-prick blood samples and symptom surveys were collected. On the second wave, there was a substantial rise in adjusted seroprevalence (50.15%, 95% CI [45.92 – 54.40]) compared with the first wave (24.82 %, 95%CI [22.49 – 27.25]), with females maintaining a higher seroprevalence (53.89; 95% CI [48.48-59.23]) vs. 45.49; 95% CI [38.98-52.12], p=0.042) compare to males. Those under 18 years of age had the highest IgG seropositivity: the 12–17 age group during the second wave (85.14%) and the 2–11 age group (25.25%) during the first wave. Nasal congestion and cough were symptoms associated with seropositivity, unlike the first wave.Conclusions/Significance In Tumbes, the seroprevalence of COVID-19 increased by twofold compared to the initial wave. Inadequate infrastructure and limitations in human resources and supplies in healthcare facilities made the Peruvian health system collapse. We must include in epidemiological surveillance mHealth tools that enable real-time reporting of new cases. Working alongside the community is the only way to improve any new intervention strategy to prevent or control a new pandemic.Author summary In Peru, the healthcare system was overwhelmed by the COVID-19 pandemic due to the lack of hospital capacity, oxygen supply, political unrest, and a fragmented healthcare system. During the first wave, the prevalence ranged from 20.8% to 72%, and it was predicted that the second wave would be disastrous. To assess the seroprevalence of SARS-CoV-2, a cross-sectional study was conducted in the settlement “AAHH Las Flores” located in front of Tumbes National University’s main campus. A door-to-door intervention was conducted, and a total of 580/781 (74.26%) individuals over than 2 years and above agreed to participate. After adjusting for sensitivity and specificity, the calculated adjusted seroprevalence was 50.15%. Women had a slightly higher adjusted seroprevalence compared to men, and the age groups with the highest prevalence of IgG seropositive were from 12 to 17 years, from 30 to 59 years, and older than 60 years. More than 80% of seropositive patients were asymptomatic in all age groups. The study’s findings suggest that COVID-19 transmission in the settlement was higher during the second wave, and asymptomatic individuals could have played a critical role in spreading the virus.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.protocols.io/view/prevalencia-de-covid-19-asociada-con-dengue-y-mala-kqdg39dk1g25/v1 Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Cayetano Heredia University gave us the ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are fully available without restriction